Looks cheap at this price.
and the technology looks sound, one for the future perhaps.

Inion Oy
29 October 2007



Inion Receives Marketing Clearance for Inion BioRestore(TM) Synthetic Bioactive
and Biodegradable Bone Filler Material in Europe

Tampere, Finland and Guildford, UK. 29 October 2007...Inion (LSE: IIN.L), a
company focused on the development of novel biodegradable medical implants, has
received CE Mark* from the British Standards Institution (BSI) for its Inion
BioRestore(TM) bioactive and biodegradable implant material. Inion BioRestore
(TM) has been approved for use in orthopaedic trauma, spine,
cranio-maxillofacial and dental procedures, to fill bony voids or gaps in the
skeleton that may result from surgery or from traumatic injury.

Chris Lee, Inion's CEO, said: 'Inion BioRestore(TM) is now cleared for this wide
range of surgical procedures in both the USA and Europe, and is another
development milestone we have hit as planned during 2007. This new product will
complement and enhance our focused product offering in our core orthopaedic
trauma and spine areas. It is particularly important in the spine area as we
also recently received CE Mark for our Inion S-2(TM) spinal fusion and graft
containment system, which combined with the previously cleared Inion S-1(TM)
system, means we can market our innovative biodegradable implants for
applications over the entire spine.'

*CE Mark is issued by a number of accredited bodies to medical device
manufacturers prior to commercial distribution in the European Union.



About Inion BioRestore(TM)

Inion BioRestore(TM) is a state-of-the-art synthetic bioactive and biodegradable
bone grafting substitute material made from bioactive glass fibres. It is
designed for use alone or in conjunction with Inion's other biodegradable
products, offering many clinical advantages to surgeons and patients.

Inion BioRestore(TM) can be cut or shaped precisely to fit the defect and
provides a highly porous scaffold onto which the patient's new bone can grow,
allowing complete repair of the defect. A key property of Inion BioRestore(TM)
material is its bioactivity; in preclinical studies, it demonstrated
osteoconductive and osteostimulative properties, accelerating new bone formation
while gradually degrading over approximately six months to allow bone to fill
the void.

Inion BioRestore(TM) is designed to replace current bone grafting techniques in
certain surgical procedures, where it offers other important advantages,
primarily in that its synthetic origin excludes risks of disease transmission
and overcomes the limitations in quantity and quality of available bone graft.

According to Millennium Research Group and Knowledge Enterprises, the US market
for bone graft substitutes is estimated at $1.5 billion between 2007 and 2011.
The market for synthetic bone graft substitutes is approximately $158 million
and is growing at a compound annual rate of 10%. Bone graft substitutes are
used in the following application areas: spine (approximately 63% of market
value), orthopaedic trauma (17%), dental (17%), reconstructive surgery (i.e.
hips, knees, 2%), cranio-maxillofacial (CMF, 1%) (NB: numbers do not add to 100%
due to rounding). The market outside the US is estimated to be worth 36% of the
US market.


-Ends-

Inion Oy
08 January 2008



Inion stengthens international patent position for Inion OptimaPLUSTM bioactive
materials technology



Tampere, Finland and Guildford, UK. 8 January 2008...Inion Oy (LSE: IIN.L) ('
Inion'), a company focused on the development of novel biodegradable medical
implants, has been granted a patent in Australia covering a method for creating
its Inion OptimaPLUSTM bioactive and biodegradable material. Inion OptimaPLUSTM
is a material consisting of a specific solid matrix of resorbable polymer in
which N-methyl-2-pyrrolidone (NMP) is dispersed in amounts sufficient to
stimulate bone growth. This material can be fashioned into medical implants to
support and enhance bone fracture healing.



The Australian patent (AU 2002346767) also covers other polymer compositions
containing NMP and strengthens Inion's international patent position in this
area of next-generation bioactive biomaterials. The equivalent patent is
already issued in the USA (US 6 926 906) and additional patent applications for
this novel technology are in progress in Europe, Brazil, Canada, China, Korea
and Japan.



Mr Chris Lee, Inion's Chief Executive Officer, commented: 'This new patent is an
important enhancement of our IP portfolio in the development of novel
biomaterials with bioactive qualities for creating next-generation medical
implants.'



- ends -